Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Lassen

Showing results (91-100 of 135) with videos related to

Pageof 14
Sort By:
Thrombosis Research|July 1, 1990
Association between plasma levels of tissue plasminogen activator and postoperative deep vein thrombosis--influence of prophylaxis with a low molecular weight heparin. The Venous Thrombosis GroupJ V Sørensen, L C Borris, M R Lassen, et al.
The Journal of Bone and Joint Surgery. British Volume|February 11, 2012
Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trialsG E Raskob, A S Gallus, G F Pineo, et al.
Haemostasis|January 1, 1992
Potential influence of observer variation in thromboprophylactic trialsP Wille-Jørgensen, L C Borris, M R Lassen, et al.
The International Journal of Risk & Safety in Medicine|March 21, 2013
Survival in patients undergoing total hip arthroplasty in relation to thromboprophylaxis with low molecular weight heparin: a long-term follow-up studyB S Andersen, H P Jensen, L C Borris, et al.
Journal of Thrombosis and Haemostasis : JTH|January 3, 2013
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroupsG F Pineo, A S Gallus, G E Raskob, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 1, 1992
Reduction of plasma levels of prothrombin fragments 1 and 2 during thromboprophylaxis with a low-molecular-weight heparinJ V Sørensen, M R Lassen, L C Borris, et al.
Alimentary Pharmacology & Therapeutics|April 15, 2004
Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitisS Bloom, S Kiilerich, M R Lassen, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|November 1, 1993
Haemostatic activation in patients with head injury with and without simultaneous multiple traumaJ V Sørensen, H P Jensen, H B Rahr, et al.
The New England Journal of Medicine|June 27, 2008
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplastyMichael R Lassen, Walter Ageno, Lars C Borris, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1991
Clinical trials with low molecular weight heparins in the prevention of postoperative thromboembolic complications: a meta-analysisM R Lassen, L C Borris, H M Christiansen, et al.
Pageof 14

Showing results (91-100 of 135) with videos related to

Sort By:
Pageof 14
Thrombosis Research|July 1, 1990
Association between plasma levels of tissue plasminogen activator and postoperative deep vein thrombosis--influence of prophylaxis with a low molecular weight heparin. The Venous Thrombosis GroupJ V Sørensen, L C Borris, M R Lassen, et al.
The Journal of Bone and Joint Surgery. British Volume|February 11, 2012
Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trialsG E Raskob, A S Gallus, G F Pineo, et al.
Haemostasis|January 1, 1992
Potential influence of observer variation in thromboprophylactic trialsP Wille-Jørgensen, L C Borris, M R Lassen, et al.
The International Journal of Risk & Safety in Medicine|March 21, 2013
Survival in patients undergoing total hip arthroplasty in relation to thromboprophylaxis with low molecular weight heparin: a long-term follow-up studyB S Andersen, H P Jensen, L C Borris, et al.
Journal of Thrombosis and Haemostasis : JTH|January 3, 2013
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroupsG F Pineo, A S Gallus, G E Raskob, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 1, 1992
Reduction of plasma levels of prothrombin fragments 1 and 2 during thromboprophylaxis with a low-molecular-weight heparinJ V Sørensen, M R Lassen, L C Borris, et al.
Alimentary Pharmacology & Therapeutics|April 15, 2004
Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitisS Bloom, S Kiilerich, M R Lassen, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|November 1, 1993
Haemostatic activation in patients with head injury with and without simultaneous multiple traumaJ V Sørensen, H P Jensen, H B Rahr, et al.
The New England Journal of Medicine|June 27, 2008
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplastyMichael R Lassen, Walter Ageno, Lars C Borris, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1991
Clinical trials with low molecular weight heparins in the prevention of postoperative thromboembolic complications: a meta-analysisM R Lassen, L C Borris, H M Christiansen, et al.
Pageof 14